Belgian Retail Distributors Stock News

Q1 2026 earnings snapshot and context Melexis (ENXTBR:MELE) opened Q1 2026 reporting season with recent quarterly numbers that put revenue and EPS in clear focus, with Q4 2025 revenue at €214.5 million and basic EPS at €0.56 helping anchor the latest trailing trends. Over the past few quarters, the company has seen revenue move from €197.4 million in Q4 2024 to €198.2 million in Q1 2025, €211.6 million in Q2 2025, €215.3 million in Q3 2025 and €214.5 million in Q4 2025. Quarterly basic EPS...

ageas (ENXTBR:AGS) has completed the acquisition of the remaining stake in AG Insurance, consolidating full ownership of its Belgian insurance business. The company has issued new and treasury shares to BNP Paribas Cardif, increasing its outstanding share capital and reshaping its shareholder base. ageas is accelerating expansion in India, aiming for a top 10 position through acquisitions and deeper bancassurance partnerships. For investors watching ENXTBR:AGS, these moves come as the share...

Recticel (ENXTBR:RECT) has wrapped up FY 2025 with second half revenue of €319.9 million and basic EPS of €0.19. This is set against a trailing twelve month revenue base of €655.1 million and EPS of €0.09 that reflects the impact of a one off €11.7 million loss on profitability. The company has seen revenue move from €610.2 million in the trailing twelve months to June 2024 to €655.1 million in the latest trailing period, while trailing EPS has shifted from €0.29 to €0.09 as margins have been...

Campine NV's ( EBR:CAMB ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...

If you are wondering whether ageas at €66.55 still offers value or if most of the upside is already reflected in the price, you are asking the right question. The stock has seen a 7.0% return over the last 30 days and a 25.7% return over 1 year, while the 3 year and 5 year returns sit at 91.1% and 68.8% respectively, even with a 2.2% decline in the last week and a 9.4% return year to date. Recent coverage around ageas has focused on its position in the insurance sector and how investors are...

Investors may be wondering if Umicore at around €17.20 is still good value after its recent rebound, or if the easy gains are already behind it. The stock shows mixed returns, with a 7.2% gain over the last month and a 108.2% return over the past year, but declines of 7.5% year to date, 34.4% over three years, and 61.6% over five years. Recent coverage has focused on Umicore as investors reassess materials and specialty chemicals businesses, paying close attention to balance sheet strength...

As geopolitical tensions and economic uncertainties weigh on European markets, with the STOXX Europe 600 Index experiencing a notable decline, investors are increasingly seeking stability in growth companies with strong insider backing. In such an environment, stocks that exhibit robust growth potential coupled with high insider ownership can offer a compelling proposition due to the alignment of interests between shareholders and company insiders.

Umicore (ENXTBR:UMI) sits at the center of several key materials themes that many investors track, from battery components to recycling. Its recent share performance is a fresh prompt to reassess the stock. See our latest analysis for Umicore. At a share price of €17.06, Umicore has seen a 6.36% 1 month share price return but a 20.13% 3 month share price decline. The 1 year total shareholder return of 109.58% contrasts with weaker 3 and 5 year total shareholder returns, which indicates that...

Why Anheuser-Busch InBev (ENXTBR:ABI) is Back on Investor Radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after recent share price moves and steady longer term returns, prompting investors to reassess how its global beer and beverage footprint lines up with current valuations. See our latest analysis for Anheuser-Busch InBev. Recent trading has been mixed, with a 5.32% 1 month share price return and a 14.26% year to date share price return contributing to a 10.01% 1 year...

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.

Q1 2026 earnings snapshot and how the story is evolving Xior Student Housing (ENXTBR:XIOR) has opened 2026 with Q1 revenue of €58.6 million and basic EPS of €1.04, putting fresh numbers behind a share price of €27.45. Over the recent reporting periods, revenue has ranged from €50.6 million to €62.5 million per quarter, while basic EPS has swung between a small quarterly loss of €0.01 and a high of €1.04, giving investors a clear view of how sensitive per share results have been to shifts in...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...

Anheuser-Busch InBev commits $600 million to expand U.S. investment and workforce development. Plan includes new technical training centers and a large scale upskilling program across manufacturing roles. Company also expands its veteran hiring initiatives to support transitions into private sector careers. Anheuser-Busch InBev, listed as ENXTBR:ABI, is putting fresh attention on its U.S. footprint with this $600 million package focused on facilities and people. The company’s shares...

argenx (ENXTBR:ARGX) drew attention after presenting new VYVGART and neuromuscular pipeline data at the 2026 American Academy of Neurology meeting, together with an ongoing FDA priority review for a supplemental label expansion. See our latest analysis for argenx. The recent clinical updates and FDA priority review arrive after a 17.5% 1 month share price return and a year to date share price decline of 5.3%, while the 1 year total shareholder return is 28.9% and the 5 year total shareholder...

If you are wondering whether argenx is priced attractively or already reflecting high expectations, especially after a strong run in recent years, this article explains what the current share price might indicate about value. argenx recently closed at €707.6, with returns of 4.5% over 7 days, 21.0% over 30 days, 35.0% over 1 year, 100.6% over 3 years and 187.3% over 5 years. Year to date, the stock shows a 2.2% decline. Recent headlines around argenx have kept attention on the company and...

Groupe Bruxelles Lambert (ENXTBR:GBLB) just reported full year 2025 results, posting sales of €6,221.7 million and a net loss of €625.4 million, a swing from net income in the prior year. See our latest analysis for Groupe Bruxelles Lambert. The earnings swing to a net loss comes as the share price has still delivered a 1 month share price return of 4.7% and a 1 year total shareholder return of 25.8%, suggesting that investors may be reassessing long term prospects rather than reacting only...

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...

Recently, argenx reported the completion of a key CIDP switch study for its efgartigimod therapy, marking a meaningful clinical milestone in its autoimmune portfolio. This progress in CIDP strengthens the case for efgartigimod as a potentially broader platform therapy across neuromuscular autoimmune indications. Next, we will examine how completion of the CIDP switch study might influence argenx’s investment narrative and outlook for efgartigimod. Capitalize on the AI infrastructure...

Fagron (ENXTBR:FAGR) put acquisitions back in focus in its Q1 2026 trading update, pairing 10% topline growth with confirmation that recent deals, including Pharmavit in the Netherlands, are being integrated as planned. See our latest analysis for Fagron. The share price sits at €22.5, with a 3.45% year to date share price return and a 17.69% one year total shareholder return, which hints that investors are gradually warming to Fagron's growth and acquisition story. If Fagron's acquisition...

Solvac S.A.'s ( EBR:SOLV ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Why Azelis Group is on investors’ radar Azelis Group (ENXTBR:AZE) has caught investor attention after a recent share price move, with the stock showing a mix of short term gains and longer term weakness that raises fresh questions about its current valuation. See our latest analysis for Azelis Group. The recent rally, including a 23.88% 30 day share price return and 5.37% 7 day share price return to €9.415, comes against a much weaker backdrop, with a 36% 1 year total shareholder return...

BlackRock, Inc. disclosed that its direct voting rights in Umicore (ENXTBR:UMI) moved above the 5% threshold, then later fell back below 5%, within a short period. The changes were reported through regulatory filings, highlighting shifts in a major institutional investor's position in the company. Crossing the 5% level triggers mandatory disclosure rules, which can draw market attention to institutional ownership in Umicore. Umicore operates in materials technology and recycling, with...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...